38 results on '"Shcheblyakov, Dmitry V."'
Search Results
2. Structural insight into recognition of Clostridioides difficile toxin A by novel neutralizing nanobodies targeting QTIN-like motifs within its receptor-binding domain
3. Sputnik V protection from COVID-19 in people living with HIV under antiretroviral therapy
4. An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine “Sputnik Light” for prevention of coronavirus infection in healthy adults
5. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
6. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia
7. Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period
8. Safety and immunogenicity of rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine against SARS-CoV-2 in healthy adolescents: an open-label, non-randomized, multicenter, phase 1/2, dose-escalation study
9. rAAV expressing recombinant antibody for emergency prevention and long-term prophylaxis of COVID-19
10. Single-domain antibody delivery using an mRNA platform protects against lethal doses of botulinum neurotoxin A
11. Revaccination in Age-Risk Groups with Sputnik V Is Immunologically Effective and Depends on the Initial Neutralizing SARS-CoV-2 IgG Antibodies Level
12. Estimation of anti-orthopoxvirus immunity in Moscow residents and potential risks of spreading Monkeypox virus
13. Cross-Reactive Fc-Fused Single-Domain Antibodies to Hemagglutinin Stem Region Protect Mice from Group 1 Influenza a Virus Infection
14. Single-domain antibody delivery using an mRNA platform protects against lethal doses of botulinum neurotoxin A
15. Cross-reactive single-domain antibodies to hemagglutinin stem region protect mice from group 1 influenza A virus infection
16. rAAV expressing recombinant neutralizing antibody for the botulinum neurotoxin type A prophylaxis
17. Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates
18. Retention of Neutralizing Response against SARS-CoV-2 Omicron Variant in Sputnik V-Vaccinated Individuals
19. Boosting of the SARS-CoV-2–Specific Immune Response after Vaccination with Single-Dose Sputnik Light Vaccine
20. Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern
21. Development of Neutralizing Nanobodies to the Hemagglutinin Stem Domain of Influenza A Viruses
22. Revaccination in Age-Risk Groups with Sputnik V Is Immunologically Effective and Depends on the Initial Neutralizing SARS-CoV-2 IgG Antibodies Level.
23. Single-domain antibodies efficiently neutralize SARS-CoV-2 variants of concern, including Omicron variant
24. Boosting of the SARS-CoV-2-specific immune response after vaccination with single-dose Sputnik Light vaccine
25. One-shot immunization with Sputnik Light (the first component of Sputnik V vaccine) is effective against SARS-CoV-2 Delta variant: efficacy data on the use of the vaccine in civil circulation in Moscow
26. Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants
27. Data discrepancies and substandard reporting of interim data of Sputnik V phase 3 trial – Authors' reply
28. Impact of pathogen reduction methods on immunological properties of the COVID‐19 convalescent plasma
29. An Open, Non-Randomised, 1/2 Phase Study on the Safety, Tolerability, and Immunogenicity of Single Dose 'Sputnik Light' Vaccine for Prevention of Coronavirus Infection in Healthy Adults
30. Sputnik V Protection from COVID-19 of HIV-Infected Individuals Under Art
31. Impact of pathogen reduction methods on immunological properties of the COVID-19 convalescent plasma
32. Safety and efficacy of the Russian COVID-19 vaccine: more information needed – Authors’ reply
33. Stimulation of Dectin-1 and Dectin-2 during Parenteral Immunization, but Not Mincle, Induces Secretory IgA in Intestinal Mucosa
34. Powerful Complex Immunoadjuvant Based on Synergistic Effect of Combined TLR4 and NOD2 Activation Significantly Enhances Magnitude of Humoral and Cellular Adaptive Immune Responses
35. Genetic Passive Immunization with Adenoviral Vector Expressing Chimeric Nanobody-Fc Molecules as Therapy for Genital Infection Caused by Mycoplasma hominis
36. Combined Stimulation of Toll-Like Receptor 5 and NOD1 Strongly Potentiates Activity of NF-κB, Resulting in Enhanced Innate Immune Reactions and Resistance to Salmonella enterica Serovar Typhimurium Infection
37. Combined Stimulation of Toll-Like Receptor 5 and NOD1 Strongly Potentiates Activity of NF-?B, Resulting in Enhanced Innate Immune Reactions and Resistance to Salmonella entericaSerovar Typhimurium Infection
38. Camelid VHHs Fused to Human Fc Fragments Provide Long Term Protection Against Botulinum Neurotoxin A in Mice.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.